Cargando…
Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke
Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only a small fraction of potentially eligible stroke patients receive this medication. There seems to be a fear among practitioner...
Autores principales: | Bruce, Nhu T., Neil, William P., Zivin, Justin A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Current Science Inc.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085754/ https://www.ncbi.nlm.nih.gov/pubmed/21424751 http://dx.doi.org/10.1007/s11936-011-0122-0 |
Ejemplares similares
-
Functional Outcome Measures of Recombinant Tissue Plasminogen
Activator–Treated Stroke Patients in the Telestroke Technology
por: Gainey, Jordan, et al.
Publicado: (2018) -
The Role of Hospitalists in the Acute Care of Stroke Patients
por: Amin, Alpesh, et al.
Publicado: (2010) -
Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
por: Abcede, Hermelinda G., et al.
Publicado: (2010) -
Principled Versus Statistical Thinking in Diagnosis and Treatment of Stroke
por: Helgason, Cathy M., et al.
Publicado: (2010) -
Galectins in the Pathogenesis of Cerebrovascular Accidents: An Overview
por: Abel, William F, et al.
Publicado: (2019)